广誉远：2025年上半年归属股东净利润为7685.71万元，同比上涨28.95%丨财面儿

Core Insights - The company reported a revenue of 779 million yuan for the first half of 2025, representing a year-on-year growth of 18.14% [1] - The net profit attributable to shareholders reached 76.86 million yuan, an increase of 28.95% compared to the previous year [1] Financial Performance - Total assets as of June 30, 2025, amounted to 2.454 billion yuan, while the net assets attributable to shareholders were 1.647 billion yuan [1] - The company added 43 new terminal stores during the reporting period, bringing the total number of terminal stores to 505 as of June 30, 2025 [1] Product and Market Overview - The company's pharmaceutical industry is divided into three main segments: traditional Chinese medicine, premium Chinese medicine, and health wine, based on product positioning and sales channels [1] - The company offers eight dosage forms, including pills, powders, tablets, hard capsules, granules, mixtures, wine preparations, and decoction pieces, with a total of 104 drug registration certificates, one health product registration certificate, one food license, one liquor license, 264 domestic trademarks, and 28 patented technologies [1]